Home page  |  Help  |  Clear
English  |  French
 Search  |  Categories  |  Titles A-Z  |  Countries  |  Compare countries  |  Index  
Full TOC
Expand Document
Expand Chapter
Preferences

close this bookGuidelines to Antiretroviral Drug Therapy in Kenya (WHO; 2001; 78 pages)
View the documentFOREWORD
View the documentACKNOWLEDGMENT
Open this folder and view contentsCHAPTER ONE: INITIATING ANTIRETROVIRAL THERAPY
Open this folder and view contentsCHAPTER TWO: MONITORING AND CHANGING THERAPY
Open this folder and view contentsCHAPTER THREE: PHARMACOTHERAPEUTICS OF ARVS
Open this folder and view contentsCHAPTER FOUR: GUIDELINES FOR THE USE OF ANTIRETROVIRAL DRUGS IN PAEDIATRIC HIV INFECTION
Open this folder and view contentsCHAPTER FIVE: MANAGEMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTED PREGNANT WOMEN AND PREVENTION OF MOTHER TO CHILD TRANSMISSION (MTCT) OF HIV
Open this folder and view contentsCHAPTER SIX: SPECIAL CONSIDERATIONS
Open this folder and view contentsCHAPTER SEVEN: WHEN TO STOP TREATMENT (INTERRUPTIONS)
Open this folder and view contentsCHAPTER EIGHT: GUIDELINES FOR POST EXPOSURE PROPHYLAXIS
View the documentCHAPTER NINE: ACCESS TO DRUGS IN KENYA
close this folderAPPENDICES
View the documentI. Drug to drug interactions
View the documentII. Drug to drug interactions (continued)
View the documentIII. Drug Interactions Between Antiretrovirals and Other Drugs
View the documentIV. Nucleoside Reverse Transcriptase Inhibitors (NRTIS)
View the documentV. Drug Interactions: Protease Inhibitors
View the documentVI. Drug Interactions: Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors - Cont.
View the documentVII. Drug That Should Not be Used With Antiretrovirals
View the documentVIII. Drugs that should not be used with Protease Inhibitors Antiretrovirals
View the documentIX. HIV-related drugs with overlapping toxicities
View the documentX. Anti-retroviral therapy for preventing MTCT
View the documentBACK COVER
 

X. Anti-retroviral therapy for preventing MTCT

STUDY

DRUG

ANTEPARTUM

INTRAPARTUM

POSTPARTUM

INFANT

REDUCTION IN MTCT

PACTOG 076
Non Breast feeding

AZT

100 mg p.o. 5 times daily starting at 14-34 week gestation.

1v 2mg/kg loading, then 1 mg/kg/hr

No

2mg/kg p.o. 6 hourly for 6 weeks

68% (infection status at 18 months

Thailand
Non breast feeding

AZT

300 mg p.o. bd, p.o starting at 36 weeks gestation

300mg p.o 3hrly

No

No

50% (infection status at 6 months age)

Cote D voire
Breast feeding

AZT

300 mg p.o. Bd, p.o. starting at 36 weeks gestation

300mg p.o 3hrly

No

No

47% (infection status at 6 weeks age)

Cote D voire
Burkina Faso
breast feeding

AZT

300 mg p.o. bd, starting at 36 weeks gestation

600mg p.o at the onset of labour

300mg bd for 1 week

No

38% (infection status at 6 months age)

Africa-Petra
Arm A 67%
Breast feeding

AZT +3TC

300mg AZT + 150mg +3TC . starting at 36 weeks gestation

300mg AZT+ 150mg 3TC p.o 3 hourly

300mg AZT + 150mg 3TC p.o bd for 1 week

AZT 4mg/kg + 3TC 2mg/ kg p.o bd for 1 week

38% (infection status at 6 months age)

Africa-Petra
Arm B 67%
Breast feeding

AZT 300mg +3TC 150mg (combivir)

No

300mg AZT+ 150mg 3TC p.o 3 hourly

300mg AZT + 150mg 3TC p.o bd for 1 week

AZT 4mg/kg + 3TC 2mg/ kg p.o bd for 1 week

37% (infection status at 6 weeks age)

VIVNET
Breast feeding

 

No

200mg single dose at the onset of labor

No

2mg/kg single dose in the first 72 hours

47% (infection status at 6 weeks)

Design, layout, colour separations and printing done by
TESSA Productions Co. Ltd. Box 418 Sarit centre: Tel: 443248/446570

to previous sectionto next section

Please provide your feedback English  |  French